Articles published by Segal Trials

Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study

Today 11:33 EDT

From Segal Trials

Via Business Wire

As Federal Fast-Tracking Accelerates Psychedelic Therapies, Segal Trials Is Positioned to Support the Next Phase of Clinical Development

April 22, 2026

From Segal Trials

Via Business Wire

Segal Trials Participates in Research Leading to FDA Approval of Tonmya™, the First New Fibromyalgia Treatment in More Than 16 Years

September 10, 2025

From Segal Trials

Via Business Wire

Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics

July 07, 2025

From Segal Trials

Via Business Wire

Segal Trials Investigator Dr. Olga Lapeyra Contributes to Pivotal Migraine Study Leading to FDA Approval of Atzumi™

June 24, 2025

From Segal Trials

Via Business Wire

Segal Trials Leads Phase 2 Schizophrenia Trial of LB-102 Toward Primary Endpoint

January 22, 2025

From Segal Trials

Via Business Wire

Segal Trials Plays Key Role in FDA Approval of COBENFY™, A New Era in Schizophrenia Treatment

October 04, 2024

From Segal Trials

Via Business Wire

Segal Trials to Speak on Panel at Latina Expo 2024, Hosted by CISCRP, Focusing on Diversity in Clinical Research

February 05, 2024

From Segal Trials

Via Business Wire

Segal Trials Showcased Leadership in CNS Research and Psychedelic Studies at CNS Summit 2023

December 01, 2023

From Segal Trials

Via Business Wire

Segal Trials Participation in Study Shows Positive Results From Phase 3 EMERGENT-2 KarXT in Schizophrenia

August 23, 2022

From Segal Trials

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.